Press releases
GSK European regulatory update on Pandemrix™
CHMP concludes that data are insufficient to establish a causal relationship between Pandemrix and narcolepsy.
First African country introduces GSK’s pneumococcal vaccine through innovative financing mechanism
GlaxoSmithKline (GSK) announced the incorporation of its pneumococcal vaccine into the Kenyan national immunisation programme. Kenya is the first African country to receive pneumococcal vaccines through the innovative financing mechanism known as the Advance Market Commitment (AMC), which is designed to bring heavily discounted vaccines to children living in the world’s poorest countries.
GlaxoSmithKline moving to new building at Philadelphia Navy Yard
GlaxoSmithKline (NYSE:GSK), a leading worldwide research-based pharmaceutical company, and Liberty Property Trust (NYSE:LRY) today announced that GSK has signed a 15.5-year lease for a new building to be developed by Liberty Property Trust and Synterra Partners. Located at Five Crescent Drive in the Navy Yard Corporate Center, the 205,000 square-foot, four-story facility will be designed to achieve LEED® Platinum certification, the highest possible designation in the internationally-recognized sustainable building rating system. The project represents an $81 million investment by Liberty.
GSK revises US Avandia label to include new restrictions on use
GlaxoSmithKline (GSK) today announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines (Avandia®, Avandamet® and Avandaryl®) to include additional safety information and restrictions on the use of these medicines. The new label content reflects the US Food and Drug Administration’s review of cardiovascular event data in type 2 diabetes patients treated with Avandia, and follows a meeting of the joint Advisory Committees in July 2010 and a decision in September 2010 by the FDA to restrict access to these medicines.
GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results for Benlysta® in The Lancet
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced publication of the BLISS-52 study of Benlysta® (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus (SLE) in The Lancet .
GSK results announcement for the fourth quarter
Strategic progress drives positive underlying sales growth*,increasing pipeline potential and improved cash generation. Increased dividend and new long-term share buy-back programme enhance returns to shareholders.
GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD
GSK and Theravance, Inc. today announced major milestones in two clinical development programmes focused on new treatments for patients with COPD, a leading cause of chronic illness and death worldwide.
Update on Pandemrix™ and interim Finnish report on narcolepsy
GSK is aware of today’s interim report by the Finnish National narcolepsy committee [1] on their investigation into reported cases of narcolepsy in Finland. This investigation is independent of a broader ongoing European Medicines Agency (EMA) investigation initiated in 2010. GSK is reviewing the report and believes it would be premature to draw any conclusions on a potential association between Pandemrix and narcolepsy until this European investigation has been completed.
GSK announces the sale of its entire shareholding in Quest Diagnostics
GlaxoSmithKline plc (“GSK”) announces that it has sold its entire holding of 30,755,151 shares of common stock in Quest Diagnostics Inc. (“Quest”). The sale comprised a secondary public offering by GSK (the “Offering”) and an accompanying repurchase of shares by Quest (the “Repurchase”). GSK originally acquired the shareholding as partial consideration for the sale of its clinical laboratories business in 1999 and has since gradually reduced its stake in stages.
GSK and Actelion discontinue clinical development of almorexant
GlaxoSmithKline (GSK) and Actelion Ltd (SIX: ATLN) today announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued. This decision follows a review of data from additional clinical studies, which were conducted to further establish the clinical profile of almorexant, including the tolerability profile.
